Evidence map›Paper›PMID 42232504›Full record

ArticlebioRxiv : the preprint server for biology2026

Targeting the Mitochondrial Phenotype in Cockayne Syndrome Patient Cells: From Bioenergetic Fragility to Pharmacologic Rescue.

Melis Kose, Elizabeth M McCormick, Kelsey Keith, Cristina Remes, Suraiya Haroon, Eiko Nakamaru-Ogiso, Marni J Falk

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Melis KoseMitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.ORCID 0000-0003-2255-3725
Elizabeth M McCormickMitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
Kelsey KeithDepartment of Biomedical and Health Informatics, The Children's Hospital of Philadelphia, Philadelphia, PA.
Cristina RemesMitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
Suraiya HaroonMitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
Eiko Nakamaru-OgisoMitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.
Marni J FalkMitochondrial Medicine Frontier Program, Division of Genetic and Genomic Medicine, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA.

Funding

The North American Mitochondrial Disease Consortium (NAMDC)U54NS078059 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI HIRANO, MICHIO · 2011 to 2023
$17.5M
Mitochondrial respiratory chain disease mechanistic and therapeutic modelingR35GM134863 · NIGMS · CHILDREN'S HOSP OF PHILADELPHIA · PI MARNI J FALK · 2020 to 2026
$4.3M
NIGMS NIH HHS R35 GM134863NINDS NIH HHS U54 NS078059
6 · The paper itself

Abstract

Background: Cockayne syndrome (CS), primarily caused by autosomal recessive pathogenic variants in Methods: We characterized mtDNA content, respiratory chain (RC) protein abundance, mitochondrial biogenesis signaling pathways, and oxidative phosphorylation capacity in primary fibroblasts from two siblings with identical compound heterozygous Results: Patient fibroblasts exhibited several hallmarks of PMD, including reduced mtDNA content, decreased expression of complex I subunit NDUFB8, elevated expression of TOM20 with paradoxically decreased PGC1α suggestive of impaired mitophagic clearance, and decreased mitochondrial respiratory capacity. Under combined metabolic stress, ATP-levels indicative of survival in CS patient fibroblasts selectively collapsed to ~20% of controls. Five dual-rescue compounds, defined as agents that reproducibly restored ATP-based cell survival in both patient fibroblast lines under stress, were identified, including Conclusions:

Indexed as

antioxidantsCockayne syndrome group B protein (CSB)Complex IERCC6FibroblastsMitochondrial dysfunctionOxidative stress

Identifiers

PMID42232504
PMCPMC13225278

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.